Funding for this research was provided by:
Health Research Board (HRA-POR-2015-1099, ILP-POR-2017-024)
European Research Council (ERC-2007-StG 207777)
Science Foundation Ireland (16/FRL/3845)
Received: 15 October 2019
Revised: 18 February 2020
Accepted: 27 February 2020
First Online: 13 March 2020
Ethics approval and consent to participate
: All work was approved by the Animal Care in Research Ethics Committee of the National University of Ireland, Galway, and licensed by the Health Products Regulatory Agency,
: Not applicable.
: Dr. Steve Elliman is the Chief Scientific Officer, Dr. Lisa O’Flynn is the Head of Process Development, and Ms. Emma Horan is a Cell Manufacturing Technician at Orbsen Therapeutics Ltd., Galway, Ireland, a company which is developing the Syndecan-2 positive mesenchymal stromal cells for therapeutic purposes. Prof. Timothy O’Brien and Prof. Frank Barry are directors of and equity holders in Orbsen Therapeutics. The other authors declare no competing interests.